Xu Jing, Wei Qichun, He Zhixing
Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Institute of Basic Research in Clinical Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Front Oncol. 2020 Aug 14;10:1562. doi: 10.3389/fonc.2020.01562. eCollection 2020.
The receptor-interacting protein kinase 4 (RIPK4), a member of the RIPK family, was originally described as an interaction partner of protein kinase C (PKC) β and PKCδ. RIPK4 is identified as a key regulator of keratinocyte differentiation, cutaneous inflammation, and cutaneous wound repair. The mechanism by which RIPK4 integrates upstream signals to initiate specific responses remains elusive. Previous studies have indicated that RIPK4 can regulate several signaling pathways, including the NF-κB, Wnt/β-catenin, and RAF/MEK/ERK pathways. Furthermore, RIPK4-related biological signaling pathways interact with each other to form a complex network. Mounting evidence suggests that RIPK4 is aberrantly expressed in various kinds of cancers. In several types of squamous cell carcinoma (SCC), the mutations that drive aggressive SCC have been found in RIPK4. In addition, the function of RIPK4 in carcinogenesis is probably tissue-specific, since RIPK4 can play a dual role as both a tumor promoter and a tumor suppressor in different tumor types. Therefore, RIPK4 may represent as an independent prognostic factor and a promising novel therapeutic target, which can be used to identify the risks of patients and guide personalized treatments. In future, RIPK4-interacting pathways and precise molecular targets need to be investigated in order to further elucidate the mechanisms underlying epidermal differentiation and carcinogenesis.
受体相互作用蛋白激酶4(RIPK4)是RIPK家族的成员,最初被描述为蛋白激酶C(PKC)β和PKCδ的相互作用伙伴。RIPK4被确定为角质形成细胞分化、皮肤炎症和皮肤伤口修复的关键调节因子。RIPK4整合上游信号以启动特定反应的机制仍不清楚。先前的研究表明,RIPK4可以调节多种信号通路,包括NF-κB、Wnt/β-连环蛋白和RAF/MEK/ERK通路。此外,RIPK4相关的生物信号通路相互作用形成一个复杂的网络。越来越多的证据表明,RIPK4在各种癌症中异常表达。在几种类型的鳞状细胞癌(SCC)中,已在RIPK4中发现驱动侵袭性SCC的突变。此外,RIPK4在致癌过程中的功能可能具有组织特异性,因为RIPK4在不同肿瘤类型中可同时发挥肿瘤促进剂和肿瘤抑制剂的双重作用。因此,RIPK4可能是一个独立的预后因素和有前景的新型治疗靶点,可用于识别患者风险并指导个性化治疗。未来,需要研究RIPK4相互作用的通路和精确的分子靶点,以进一步阐明表皮分化和致癌的潜在机制。